Related Experiment Video
Updated: Dec 29, 2025
09:29
Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
2.5K
Opioid Withdrawal Precipitated by Long-Acting Antagonists
Nathan M Kunzler1, Rachel S Wightman2, Lewis S Nelson3
1Harvard Affiliated Emergency Medicine Residency, Boston, Massachusetts.
The Journal of Emergency Medicine
|February 2, 2020
Summary
Managing precipitated opioid withdrawal (POW) from long-acting antagonists like naltrexone is complex. Current treatments often involve fluids, antiemetics, and benzodiazepines, with buprenorphine showing promise.
Area of Science:
- Emergency Medicine
- Pharmacology
- Toxicology
Background:
- Precipitated opioid withdrawal (POW) from long-acting opioid antagonists, such as naltrexone, presents management challenges in emergency departments.
- No established evidence-based guidelines exist for treating this syndrome.
Purpose of the Study:
- To review current practices for managing POW induced by long-acting opioid antagonists.
- To provide recommendations for treating this complex condition.
Main Methods:
- Conducted a literature search on PubMed for naltrexone-precipitated opioid withdrawal cases.
- Reviewed 27 English-language articles detailing precipitated opioid withdrawal from long-acting antagonists.
- Extracted data on precipitant, withdrawal severity, treatments, and patient response.
Main Results:
- Naltrexone was the most frequently reported antagonist.
- Common treatments included fluid replacement, benzodiazepines, antiemetics, and clonidine.
- Buprenorphine demonstrated success in reducing withdrawal severity and duration in several cases.
Conclusions:
- Management of POW from long-acting antagonists is complex with limited formal evaluation.
- Intravenous fluids, antiemetics, and benzodiazepines are commonly reported successful supportive measures.
- Partial agonists like buprenorphine are an emerging, potentially safe and effective treatment strategy.
Related Concept Videos
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
831
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
831
01:25Analgesia and Pain Management
1.4K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.4K
01:20Opioid Analgesics: Morphine and Other Natural Cogeners
770
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
770
01:28Drug-Receptor Interaction: Antagonist
4.5K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.5K
01:22Opioid Receptors: Overview
3.7K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
3.7K
01:20Desensitization and Tachyphylaxis
2.9K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
2.9K